Anti-cN-1A (NT5c1A) IBM (RDL)

Sample type: Serum
Negative
A negative result for Anti-cN-1A (NT5c1A) antibodies in the context of diagnosing Inclusion Body Myositis (IBM) indicates that these specific antibodies are not detected in the patient's blood. However, this does not definitively rule out IBM, as the disease is diagnosed through a combination of clinical features, muscle biopsy findings, and other laboratory tests. The absence of these antibodies might occur in IBM patients who do not produce this specific antibody, and it necessitates the use of other diagnostic tools, like muscle biopsies, for a conclusive diagnosis. This result can aid in differentiating IBM from other muscle disorders, though it is only one component of a comprehensive diagnostic evaluation.

Anti-cN-1A (NT5c1A) antibodies are a specific biomarker crucial in the diagnosis and understanding of Inclusion Body Myositis (IBM), a progressive and chronic inflammatory muscle disorder. These antibodies target the protein 5'-nucleotidase 1A (NT5c1A), which plays a role in purine metabolism. The presence of Anti-cN-1A (NT5c1A) antibodies is increasingly recognized as a distinctive serological marker for IBM, distinguishing it from other inflammatory myopathies. IBM is characterized by progressive muscle weakness and atrophy, primarily affecting the quadriceps and forearm muscles. Unlike other myositis forms, IBM is generally resistant to conventional immunosuppressive therapies, making its early and accurate diagnosis through biomarkers like Anti-cN-1A (NT5c1A) particularly important for patient management. The detection of these antibodies is performed using specialized serological assays, and a positive test can support the diagnosis of IBM in the appropriate clinical context. The pathogenic role of Anti-cN-1A (NT5c1A) in IBM is not fully understood, but its presence is associated with more severe disease and can provide insights into the underlying immune mechanisms. Research into Anti-cN-1A (NT5c1A) also opens avenues for understanding the complex pathophysiology of IBM and potentially developing targeted therapies in the future. As a diagnostic tool, Anti-cN-1A (NT5c1A) antibodies represent a significant advancement in differentiating IBM from other muscle diseases and tailoring patient care more effectively.

Anti-cN-1A (NT5c1A) IBM (RDL)
Healthmatters dashboard showing biomarker trend graph

Every lab result you’ve ever had, charted and explained.

Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.

Start with my report →
Beyond Anti-cN-1A (NT5c1A) IBM (RDL) — 10,000+ markers explained
One Anti-cN-1A (NT5c1A) IBM (RDL) result tells you where you are. Your history tells you where you’re heading. Upload your past lab reports and see this marker — and every marker on them —every marker charted against your own lab’s ranges.
Start with this report →
Healthmatters timeline preview showing biomarker trends over time
Clinical Sources & References

All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.

Article Review Log
Written by Healthmatters Editorial Team
Healthmatters Lifetime Plan

Pay $250. Track your health forever

One payment. No renewals. Yours for life.

10,000+ biomarkers explained · trends over time

See other plans →
Secure checkout via Stripe · GDPR & HIPAA
We accept results from any lab
LabCorp Quest Diagnostics Genova Diagnostics DUTCH Test Doctor's Data Vibrant America ZRT Laboratory Cyrex Labs + any other lab

What members are saying

★★★★★ 10,000+ happy members
★★★★★

"Watching my numbers move over the years — instead of forgetting last time's results — completely changed how I manage my health."

Daniel
Member since 2022
★★★★★

"Living across several countries made keeping my lab results organized a real challenge. Healthmatters brought my results from the USA, Spain, and Germany together — 20 years of history, with long-term trends instead of scattered reports."

Ben
Member since 2021 · tracks across countries
★★★★★

"Standard lab ranges are too wide for how I practice — 'normal' isn't optimal. I set my own bands, so a client sees yellow before a marker goes officially out of range. That's the conversation I want to be having."

Dr. Alexandra
Functional medicine · 6 yrs on Pro